Key Molecular Drivers of Chronic Lymphocytic Leukemia

被引:13
|
作者
Alsagaby, Suliman A. [1 ,2 ]
Brennan, Paul [2 ]
Pepper, Chris [2 ]
机构
[1] Majmaah Univ, Coll Sci, Dept Lab Med, King Fahd St,POB 1712, Al Zuli 11932, Riyadh Region, Saudi Arabia
[2] Cardiff Univ, Sch Med, Inst Canc & Genet, Cardiff, S Glam, Wales
来源
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2016年 / 16卷 / 11期
关键词
CLL; Molecular drivers; Pathogenicity; Prognosis; Therapy; NF-KAPPA-B; VARIABLE-REGION MUTATIONS; TREATMENT-FREE SURVIVAL; CELL-RECEPTOR; CD38; EXPRESSION; THERAPEUTIC TARGET; SF3B1; MUTATIONS; SOLUBLE CD23; DISEASE PROGRESSION; PROGNOSTIC MARKER;
D O I
10.1016/j.clml.2016.08.008
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Chronic lymphocytic leukemia (CLL) is an adult neoplastic disease of B cells characterized by variable clinical outcomes. Although some patients have an aggressive form of the disease and often encounter treatment failure and short survival, others have more stable disease with long-term survival and little or no need for theraphy. In the past decade, significant advances have been made in our understanding of the molecular drivers that affect the natural pathology of CLL. The present review describes what is known about these key molecules in the context of their role in tumor pathogenicity, prognosis, and therapy. Crown Copyright (C) 2016 Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:593 / 606
页数:14
相关论文
共 50 条
  • [1] Molecular pathogenesis of chronic lymphocytic leukemia
    Gaidano, Gianluca
    Foa, Robin
    Dalla-Favera, Riccardo
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2012, 122 (10): : 3432 - 3438
  • [2] Molecular pathogenesis of chronic lymphocytic leukemia
    Danilov, Alexey V.
    Danilova, Olga V.
    Klein, Andreas K.
    Huber, Brigitte T.
    [J]. CURRENT MOLECULAR MEDICINE, 2006, 6 (06) : 665 - 675
  • [3] Molecular biology of chronic lymphocytic leukemia
    Reed, JC
    [J]. SEMINARS IN ONCOLOGY, 1998, 25 (01) : 11 - 18
  • [4] Molecular Biomarkers in Chronic Lymphocytic Leukemia
    Malek, Sami
    [J]. ADVANCES IN CHRONIC LYMPHOCYTIC LEUKEMIA, 2013, 792 : 193 - 214
  • [5] Multivariate transcriptome analysis identifies networks and key drivers of chronic lymphocytic leukemia relapse risk and patient survival
    Ti’ara L. Griffen
    Eric B. Dammer
    Courtney D. Dill
    Kaylin M. Carey
    Corey D. Young
    Sha’Kayla K. Nunez
    Adaugo Q. Ohandjo
    Steven M. Kornblau
    James W. Lillard
    [J]. BMC Medical Genomics, 14
  • [6] Multivariate transcriptome analysis identifies networks and key drivers of chronic lymphocytic leukemia relapse risk and patient survival
    Griffen, Ti'ara L.
    Dammer, Eric B.
    Dill, Courtney D.
    Carey, Kaylin M.
    Young, Corey D.
    Nunez, Sha'Kayla K.
    Ohandjo, Adaugo Q.
    Kornblau, Steven M.
    Lillard, James W., Jr.
    [J]. BMC MEDICAL GENOMICS, 2021, 14 (01)
  • [7] Molecular genetics in chronic lymphocytic leukemia (CLL)
    Chena, C
    Pedrazzini, E
    Sarmiento, M
    Arrosagaray, G
    Bengio, R
    Slavutsky, I
    [J]. CYTOGENETICS AND CELL GENETICS, 1999, 85 (1-2): : 66 - 66
  • [8] Developing Molecular Signatures for Chronic Lymphocytic Leukemia
    Cornet, Edouard
    Debliquis, Agathe
    Rimelen, Valerie
    Civic, Natacha
    Docquier, Mylene
    Troussard, Xavier
    Drenou, Bernard
    Matthes, Thomas
    [J]. PLOS ONE, 2015, 10 (06):
  • [9] Druggable Molecular Pathways in Chronic Lymphocytic Leukemia
    Almasri, Mohammad
    Amer, Marah
    Ghanej, Joseph
    Mahmoud, Abdurraouf Mokhtar
    Gaidano, Gianluca
    Moia, Riccardo
    [J]. LIFE-BASEL, 2022, 12 (02):
  • [10] The molecular basis of familial chronic lymphocytic leukemia
    Crowther-Swanepoel, Dalemari
    Houlston, Richard S.
    [J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 (05): : 606 - 609